In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights how artificial intelligence, real-time monitoring, and historical data can aid in optimizing trial design.
In a recent video interview with Applied Clinical Trials, Dipanwita Das, CEO & co-founder at Sorcero, discussed advancements and future trends in clinical trials. Key challenges include high costs, long timelines, lack of diversity, and rigid protocols. Das highlighted technological advancements such as AI, real-time monitoring, and historical data analysis, which are all expected to optimize trial design and patient recruitment in 2025 and beyond.
ACT: What types of technology do you think clinical research experts can benefit from the most in their goal of improving patient outcomes?
Das: Technology, of course, is a huge role in transforming all of this, artificial intelligence (AI) certainly, but I think in the next one or two years, trial design optimization is where I'm excited to see the use of more historical data at scale, particularly to optimize inclusion/exclusion criteria, use of AI, and better data science and EHR analysis for patient recruitment, making sure they're actually covering all of the patient populations that need to be represented. Better real-time monitoring: real-time monitoring is just really, really difficult right now, so making sure that there is a certain degree of automated detection of data quality issues, etc., and of course, using AI for literature review protocol writing, as well as automating documentation. In the medium to long term, there are lots of other spaces in which AI and technology overall will play a huge role, from synthetic control arms to adaptive trial designs as well as digital biomarker developments, or even the idea of in silico trials, so there's a lot of exciting things coming up, but I think in the next one to two years, optimizing design, recruiting patients, and real-time monitoring is going to go a long way.
Study Finds Many Randomized Clinical Trials Have Poorly Justified Exclusion Criteria
January 21st 2025Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include at least one poorly justified exclusion, most commonly affecting pregnant or lactating individuals.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
Telemedicine Considerations When Conducting Decentralized Clinical Trials
January 14th 2025Compliance with state telemedicine requirements is imperative, as not only will most clinical trial sponsors contractually require such compliance, but non-compliance may also subject the practitioner to licensure violations and liability.